Concentric by Ginkgo and Illumina join hands for pathogen monitoring programs

Reptile8488 Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks ( NYSE: DNA ) entered into a co marketing agreement with Illumina ( NASDAQ: ILMN ) to partner on expanding biosecurity capabilities globally. The partners aim to demonstrate the use of Illumina products with Concentric's bioradar, to accelerate the expansion of the pathogen monitoring network in a way that empowers countries, as well as increase the scale and scope of pathogen genomic surveillance globally.

The shared goal is to help build local capacity for biosurveillance to empower countries rather than having to outsource biosecurity to unreliable third parties. "Without sustained investments in global early detection, we remain deeply vulnerable to the next novel pathogen threat. Through this relationship with Illumina, Concentric aims to accelerate deployment of our early warning and bioradar programs for governments worldwide as they seek to modernize defenses against biological threats," said Matt McKnight, General Manager for Biosecurity at Ginkgo Bioworks.

Ginkgo Bioworks stock price traded marginally higher 0.77% on Tuesday pre market trading. More on Ginkgo Bioworks and Illumina Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Ginkgo Bioworks stock slides despite reaffirming top line guidance for 2023 Illumina beats prelim Q4 rev expectations.